search
Back to results

Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae Compared With Vaginal Sampling in Women at Risk for Sexually Transmitted Infections (SIST'RS)

Primary Purpose

Sexually Transmitted Infection

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Vaginal, Oral and anal sampling
Sponsored by
Centre Hospitalier Régional d'Orléans
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sexually Transmitted Infection focused on measuring Sexually Transmitted Infection, PCR, C. trachomatis, N. gonorrhoeae, Screening

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Women coming for STI screening at a Cegidd Asymptomatic or not Women aged at least 18 years Having given her consent to participate Exclusion Criteria: Patient having received antibiotic treatment covering C.trachomatis and N.gonorrheae in the month preceding the screening Patient under guardianship or curatorship Patient under legal protection Pregnant or breastfeeding woman

Sites / Locations

  • CeGIDDRecruiting
  • CHRU de POITIERS
  • CH de Saint NazaireRecruiting
  • CHU de STRASBOURGRecruiting
  • CHU de ToursRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Multisite sampling

Arm Description

Vaginal, Oral and anal sampling for all participants

Outcomes

Primary Outcome Measures

Detectability of STIs in women on multisite samples
Number and percentage percentage of additional STI diagnosed with the 3 sites sampling compared to the vaginal sampling alone

Secondary Outcome Measures

Percentage of women accepting anal and oropharyngeal self-sampling
acceptability of anal and oropharyngeal self-sampling relative to vaginal self-sampling in women

Full Information

First Posted
May 3, 2023
Last Updated
July 19, 2023
Sponsor
Centre Hospitalier Régional d'Orléans
search

1. Study Identification

Unique Protocol Identification Number
NCT05872438
Brief Title
Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae Compared With Vaginal Sampling in Women at Risk for Sexually Transmitted Infections
Acronym
SIST'RS
Official Title
Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae Compared With Vaginal Sampling in Women at Risk for Sexually Transmitted Infections (STI)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2023 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Régional d'Orléans

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Screening for STIs in MSM is based on multisite samples: urine, anal and oral for PCR targeting C. trachomatis, N. gonorrhoeae, M. genitalium and T. vaginalis, whereas only vaginal self-sampling is recommended in women. Recent publications and observations suggest that a substantial number of STIs are under diagnosed with the current recommendations. The main objective of the study is to assess the number and percentage of additional C. trachomatis and N. gonorrhoeae infections diagnosed by a multiple sampling strategy in women, particularly when the vaginal sampling is negative The secondary objective will assess the acceptability of anal and oropharyngeal self-sampling relative to vaginal self-sampling in women.
Detailed Description
1500 women will be included in 5 different screening STIs centers in France based of the prevalence of STIs in this population (10% C. trachomatis) and the hypothesis that this new strategy allows to detect 20% more underdiagnosed STIs The sequential recruitment will concern women attending at one of the 5 STIs screening centers, whether they are symptomatic or not. If they agree to participate in the study, the patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed. The study will be continued until the number of patients to be included for each of the centers is obtained. The anonymized data will be entered on an Excel database. The results of the PCRs will be collected a posteriori by the IDEs to populate the database. The PCR result will be given both qualitatively (positive/negative) and CT value for C. trachomatis and N. gonorrhoeae infections.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sexually Transmitted Infection
Keywords
Sexually Transmitted Infection, PCR, C. trachomatis, N. gonorrhoeae, Screening

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Comparison of screening for two hypothesis: How many and what percentage of additional STI are diagnosed with the 3 sites sampling compared to the vaginal sampling alone?
Masking
None (Open Label)
Allocation
N/A
Enrollment
1500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Multisite sampling
Arm Type
Other
Arm Description
Vaginal, Oral and anal sampling for all participants
Intervention Type
Diagnostic Test
Intervention Name(s)
Vaginal, Oral and anal sampling
Intervention Description
The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
Primary Outcome Measure Information:
Title
Detectability of STIs in women on multisite samples
Description
Number and percentage percentage of additional STI diagnosed with the 3 sites sampling compared to the vaginal sampling alone
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
Percentage of women accepting anal and oropharyngeal self-sampling
Description
acceptability of anal and oropharyngeal self-sampling relative to vaginal self-sampling in women
Time Frame
Baseline

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women coming for STI screening at a Cegidd Asymptomatic or not Women aged at least 18 years Having given her consent to participate Exclusion Criteria: Patient having received antibiotic treatment covering C.trachomatis and N.gonorrheae in the month preceding the screening Patient under guardianship or curatorship Patient under legal protection Pregnant or breastfeeding woman
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thierry PRAZUCK, Dr
Phone
02 38 22 95 93
Email
thierry.prazuck@chr-orleans.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julienne EFFA, Dr
Organizational Affiliation
CHR d'Orléans
Official's Role
Principal Investigator
Facility Information:
Facility Name
CeGIDD
City
Orléans
ZIP/Postal Code
45000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julienne EFFA, MD
Email
julienne.effa@chr-orleans.fr
First Name & Middle Initial & Last Name & Degree
Julienne EFFA, MD
Facility Name
CHRU de POITIERS
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gwenaël LE MOAL, MD
First Name & Middle Initial & Last Name & Degree
Gwenaël LE MOAL, MD
Facility Name
CH de Saint Nazaire
City
Saint-Nazaire
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe MICHAU, MD
First Name & Middle Initial & Last Name & Degree
Christophe MICHAU, MD
Facility Name
CHU de STRASBOURG
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David REY, MD
First Name & Middle Initial & Last Name & Degree
REY David, MD
Facility Name
CHU de Tours
City
Tours
ZIP/Postal Code
37044
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume GRAS, MD
Email
guillaume.gras@me.com
First Name & Middle Initial & Last Name & Degree
Guillaume GRAS, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
36324326
Citation
Prazuck T, Lanotte P, Le Moal G, Hocqueloux L, Sunder S, Catroux M, Garcia M, Perfezou P, Gras G, Plouzeau C, Leveque N, Beby-Defaux A. Pooling Rectal, Pharyngeal, and Urine Samples to Detect Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium Using Multiplex Polymerase Chain Reaction Is as Effective as Single-Site Testing for Men Who Have Sex With Men. Open Forum Infect Dis. 2022 Oct 31;9(10):ofac496. doi: 10.1093/ofid/ofac496. eCollection 2022 Oct.
Results Reference
background
PubMed Identifier
32404400
Citation
Verougstraete N, Verbeke V, De Canniere AS, Simons C, Padalko E, Coorevits L. To pool or not to pool? Screening of Chlamydia trachomatis and Neisseria gonorrhoeae in female sex workers: pooled versus single-site testing. Sex Transm Infect. 2020 Sep;96(6):417-421. doi: 10.1136/sextrans-2019-054357. Epub 2020 May 13.
Results Reference
background
PubMed Identifier
26168051
Citation
Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, Krajden M, Ogilvie G. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. PLoS One. 2015 Jul 13;10(7):e0132776. doi: 10.1371/journal.pone.0132776. eCollection 2015.
Results Reference
background
PubMed Identifier
19028953
Citation
Alexander S, Ison C, Parry J, Llewellyn C, Wayal S, Richardson D, Phillips A, Smith H, Fisher M; Brighton Home Sampling Kits Steering Group. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect. 2008 Nov;84(6):488-92. doi: 10.1136/sti.2008.031443.
Results Reference
background
PubMed Identifier
18708480
Citation
Wayal S, Llewellyn C, Smith H, Hankins M, Phillips A, Richardson D, Fisher M; Home Sampling Kit Project Steering Group. Self-sampling for oropharyngeal and rectal specimens to screen for sexually transmitted infections: acceptability among men who have sex with men. Sex Transm Infect. 2009 Feb;85(1):60-4. doi: 10.1136/sti.2008.032193. Epub 2008 Aug 15.
Results Reference
background
Links:
URL
https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
Description
World Health Organization. Sexually transmitted infections

Learn more about this trial

Evaluation of Multisite Sampling to Detect C. Trachomatis or N. Gonorrheae Compared With Vaginal Sampling in Women at Risk for Sexually Transmitted Infections

We'll reach out to this number within 24 hrs